Male Breast Carcinoma Completed Phase 1 Trials for Cilengitide (DB11890)

IndicationStatusPhase
DBCOND0030384 (Male Breast Carcinoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01276496Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by SurgeryTreatment